Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8263589 | 0.82 | LMNA (0.81) | L3MBTL1ALDH1A1SMN1; SMN2GPBAR1KDM4E | |
| SCHEMBL16372111 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALDH1A1SMN1; SMN2GPBAR1KDM4E | |
| SCHEMBL29285658 | 0.80 | L3MBTL1 (0.67) | L3MBTL1ALDH1A1SMN1; SMN2GPBAR1KDM4E | |
| SCHEMBL23144453 | 0.78 | ALDH1A1 (0.73) | L3MBTL1ALDH1A1SMN1; SMN2GPBAR1KDM4E | |
| SCHEMBL1491825 | 0.78 | L3MBTL1 (0.72) | L3MBTL1ALDH1A1GPBAR1KDM4ETSHR | |
| SCHEMBL29811463 | 0.78 | ALDH1A1 (0.73) | L3MBTL1ALDH1A1SMN1; SMN2GPBAR1KDM4E | |
| SCHEMBL4184681 | 0.78 | GPBAR1 (0.90) | L3MBTL1ALDH1A1SMN1; SMN2GPBAR1KDM4E | |
| SCHEMBL3830421 | 0.78 | GPBAR1 (0.90) | L3MBTL1ALDH1A1SMN1; SMN2GPBAR1KDM4E | |
| SCHEMBL1645604 | 0.77 | APEX1 (0.72) | L3MBTL1GPBAR1KDM4ETSHRLMNA | |
| SCHEMBL16371970 | 0.77 | VCAM1 (0.70) | L3MBTL1GPBAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305899-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | HUTCHINSON FRED CANCER RES (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305899-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | HUTCHINSON FRED CANCER RES (US) | 2017-10-26 | — | — | US | disclosed |
| US-20150126519-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-07 | — | — | US | disclosed |
| US-20150126519-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305899-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | BLM, DNA2, DCLRE1B | L3MBTL1 1807/4885ALDH1A1 2061/4885SMN1; SMN2 3323/4885 |
| US-20150126519-A1 | ANTIBIOTIC COMPOUNDS AND COMPOSITIONS, AND METHODS FOR IDENTIFICATION THEREOF | BLM, DNA2, DCLRE1B | L3MBTL1 1807/4885ALDH1A1 2061/4885SMN1; SMN2 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.